Chemotherapy-induced myelosuppression (CIM) significantly impacts quality of life for patients with cancer and leads to ...

Chief of Medical Oncology and Hematology at Mercy Medical Center Dr. David Riseberg joins Jennifer Franciotti to discuss emerging therapies to treat aggressive forms of breast cancer.

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in ...

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.